Severe asthma (with high neutrophils), autoimmune diseases, i.e. rheumatoid arthritis, systemic sclerosis, and chronic kidney disease induced cardiovascular complications
Severe asthma (with high neutrophils), autoimmune diseases, i.e. rheumatoid arthritis, systemic sclerosis, and chronic kidney disease induced cardiovascular complications
FB704A can neutralize IL-6 specifically and inhibit IL-6/IL-6R classic- and trans-signaling at the same time, thereby inhibiting inflammatory responses.
Ref:
1. Source: Literature Review, Frost & Sullivan Analysis
2. European Respiratory Journal 2018 52: PA3918
3. The Potential American Market for Generic Biological Treatments and the Associated Cost Savings
http://www.sonecon.com/docs/studies/0208_GenericBiologicsStudy.pdf
Research Code | Therapeutic Area | Indication | Pre-Clinical | Phase I | Phase II | Phase III | NDA | Market | More |
---|
FB704A is a fully human monoclonal antibody that inhibits IL-6/IL-6R signaling pathway by neutralizing IL-6. IL-6 pathway has emerged as a pivotal pathway involved in immune regulation in many cancers and immune disorders.
建議您使用以下瀏覽器觀看合一網站,
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?